Eastman Kodak stock more than tripled on Tuesday after the company revealed a pivot to pharmaceuticals in support of the US response to the coronavirus pandemic. According to the Wall Street Journal, Kodak will soon play a role in curbing the US’ reliance on medicines from outside sources like China — starting with producing ingredients for generic drugs like the Donald Trump-touted hydroxychloroquine. Kodak chief exec Jim Continenza told WSJ he expects basic pharma ingredients to eventually make up 30% to 40% of the company’s overall business. Kodak took a $765 million loan from the US International Development Finance Corporation to power the shift, which…
This story continues at The Next Web
Welcome to the 'The Fact Factory' friends. Its an interesting Hot Spot which brings to you amazing and little known facts from all over the world. So, sit back, take a tour around the world and enjoy the trivia.
No comments:
Post a Comment